These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

711 related items for PubMed ID: 17183346

  • 1. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
    Doggrell S.
    Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
    [Abstract] [Full Text] [Related]

  • 2. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D, Haro JM, Martin-Morales A, von Keitz A, Riley A, Bertsch J, Belger M, Wolka AM, Beardsworth A, EDOS Group.
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
    Martin-Morales A, Haro JM, Beardsworth A, Bertsch J, Kontodimas S, EDOS Group.
    Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
    [Abstract] [Full Text] [Related]

  • 4. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE.
    Ann Pharmacother; 2005 Feb; 39(7-8):1286-95. PubMed ID: 15941818
    [Abstract] [Full Text] [Related]

  • 5. [Phosphodiesterase inhibitors: effectiveness and new applications].
    van Driel MF.
    Ned Tijdschr Geneeskd; 2006 Jul 22; 150(29):1613-6. PubMed ID: 16901064
    [Abstract] [Full Text] [Related]

  • 6. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
    Gresser U, Gleiter CH.
    Eur J Med Res; 2002 Oct 29; 7(10):435-46. PubMed ID: 12435622
    [Abstract] [Full Text] [Related]

  • 7. Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.
    Chang LL, Ma M, Allmen Hv, Henderson SC, Harper K, Hornbuckle K.
    Curr Med Res Opin; 2010 Jun 29; 26(6):1451-9. PubMed ID: 20394470
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Treatment of erectile dysfunction after radical retropubic prostatectomy with PDE5 inhibitor].
    Jin W, Huang YR.
    Zhonghua Nan Ke Xue; 2005 Sep 29; 11(9):708-12. PubMed ID: 16209216
    [Abstract] [Full Text] [Related]

  • 10. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I, Montorsi F, Jackson G, Mirone V, Chan ML, Loughney K, Vail GM, Beardsworth A.
    BJU Int; 2007 Jul 29; 100(1):122-9. PubMed ID: 17552960
    [Abstract] [Full Text] [Related]

  • 11. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.
    Mirone V, Fusco F, Rossi A, Sicuteri R, Montorsi F.
    BJU Int; 2009 May 29; 103(9):1212-7. PubMed ID: 19154480
    [Abstract] [Full Text] [Related]

  • 12. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
    Kell PD, Hvidsten K, Morant SV, Harnett JP, Bridge S.
    BJU Int; 2007 Apr 29; 99(4):860-3. PubMed ID: 17378846
    [Abstract] [Full Text] [Related]

  • 13. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
    Dunn ME, Althof SE, Perelman MA.
    Int J Impot Res; 2007 Apr 29; 19(2):119-23. PubMed ID: 16738695
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
    Ali ST.
    Pak J Pharm Sci; 2008 Jul 29; 21(3):275-81. PubMed ID: 18614424
    [Abstract] [Full Text] [Related]

  • 15. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors.
    Taylor J, Baldo OB, Storey A, Cartledge J, Eardley I.
    BJU Int; 2009 May 29; 103(10):1392-5. PubMed ID: 19154494
    [Abstract] [Full Text] [Related]

  • 16. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
    Kloner RA.
    Am J Cardiol; 2005 Dec 26; 96(12B):42M-46M. PubMed ID: 16387566
    [Abstract] [Full Text] [Related]

  • 17. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
    Vickers MA, Satyanarayana R.
    Int J Impot Res; 2002 Dec 26; 14(6):466-71. PubMed ID: 12494279
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Benefits of tadalafil in sexual activity-related time concerns].
    Yuang RQ.
    Zhonghua Nan Ke Xue; 2010 Jun 26; 16(6):572-5. PubMed ID: 20608366
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.